| Bioactivity | KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats[1]. |
| CAS | 1801243-39-9 |
| Formula | C22H29NO3 |
| Molar Mass | 355.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ippolito MJ, et al. KLS-13019, a novel structural analogue of cannabidiol (CBD) and GPR55receptor antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats. J Pharmacol Exp Ther. 2024 Aug 22:JPET-AR-2024-002190. |
KLS-13019
CAS: 1801243-39-9 F: C22H29NO3 W: 355.47
KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.